Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of LY4065967 in Healthy Japanese Participants
NCT06594159Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY4065967 (5 arms), sponsored by Eli Lilly and Company. Primary endpoints: Treatment Emergent Adverse Events, Maximum Concentration of Rosuvastatin and 1 more. Started Oct 2024; status: completed.
02
Drugs
LY4065967
Beyond the preview
Go deeper on NCT06594159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06594159.